Thursday, 16 August 2018 - 5:18
  • it
  • de
  • en
  • fr

Pfizer

FDA approves Pfizer’s Xtandi for specific prostate cancer type

Astellas and Pfizer on Friday jointly announced that FDA has approved a New Drug Application for Xtandi (enzalutamide) for a highly aggressive prostate cancer type (CRPC). The approval reflects the positive clinical data delivered by the drug during the Phase…

Pfizer to reorganize company into 3 units

Ahead of today’s opening bell, Pfizer announced big plans to reorganize the group. Starting 2019, the company will be split into 3 units: Innovative Medicines, including biosimilar and injectable drugs, and other products aimed at preventing infections in hospitals; Established…

Pfizer postponed price increases after talks with Mr. Trump

Last evening Pfizer declared it would postpone price increases on 100 products, a decision announced on July 1. The statement followed extensive discussions held yesterday between CEO Jan Reed and Donald Trump. The latter had tweeted on Monday that Pfizer…

Trump’s tweet makes Pfizer shares collapse

A tweet posted by Donald Trump has made Pfizer shares collapse. Today Mr. Trump has written: “Pfizer & others should be ashamed that they have raised drug prices for no reason. They are merely taking advantage of the poor &…

Pfizer: another biosimilar granted positive opinion by EMA CHMP

EMA Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion about Trazimera–biosimilar to Roche’s Herceptin (trastuzumab)– recommending a marketing authorization for patients with HER2 breast cancer. Trazimera is the fourth biosimilar by Pfizer to obtain positive…

Pfizer lies behind Mylan’s issues with Epipen

Mylan’s EpiPens is hard to be found in Canada and the UK and in severe shortage in the US. The problem is due to Pfizer, acting as a supplier to Mylan, which is experiencing issues in manufacturing enough product units…

Renewed speculation on Pfizer targeting AstraZeneca

AstraZeneca’s shares yesterday resumed an upward trend (London) as Streetinsider suggested that Pfizer could attempt a takeover to the UK-based group AstraZeneca. Many  analysts think that Pfizer is pursuing a major acquisition and companies such as Shire, Allergan, BMS and–more…

A puzzling Bristol-Myers Squibb

US-based Bristol-Myers Squibb on Thursday reported its first-quarter results, which have raised uncertainty about the company’s actual potential. BMS generated sales of $5.19bn, that is a +5% increase over Q1 2017, below the $5.22bn expected by analysts. Revenues from Opdivo,…

P&G targeting Pfizer’s Consumer Health arm

CNBC yesterday afternoon reported that the US giant Procter & Gamble is in talks with Pfizer to acquire the company’s Consumer Health arm. P&G, in fact, is the only potential buyer left, after Reckitt Benckiser and GlaxoSmithKline have announced they…

Good Phase III results for Pfizer’s Tafamidis

Pfizer yesterday night announced that its investigational therapy Tafamidis reduces mortality in patients with a rare heart disease (ATTR-ACT). The statement is supported by positive results from the Phase III ATTR-ACT clinical trial, conducted on 441 patients. According to experts,…

Pfizer celebrates 20 years of Viagra

On March 27th, 1998–exactly 20 years ago–Pfizer launched Viagra, which since then has been marketed in 120 countries and has delivered sales of almost $30bn. Viagra  (Sildenafil ) was discovered by Pfizer’s scientists Andrew Bell, David Brown and Nicholas Terrett….

M&A of Consumer Health units at a stalemate

The market provides with a wide range of opportunities those companies that want to enhance their Consumer Health portfolio through acquisitions. Assets are currently on sale by Germany-based Merck KGaA, intending to dismiss its Consumer Health arm for €4bn, and…

GSK as well renounces to acquire Pfizer’s Consumer Health arm

GlaxoSmithKline informed this morning in a short, concise press release that it will pull out of the process to acquire Pfizer’s Consumer Health division. CEO Emma Walmsley added that the group will keep reviewing other opportunities consistent with its strategy,…

Allergan plans restructuring

Allergan CEO Brent Sanders yesterday said at the Barclay Global Healthcare Conference that the group’s financial performances do reflect the recently-implemented strategy developed together with his team, yet the company’s share price is still too low and does not reflect…

Biogen to pay $600m for Pfizer-developed schizophrenia therapy

Biogen yesterday announced it has acquired from Pfizer the rights to the investigational PF-04958242 therapy, developed to treat some symptoms of schizophrenia, a condition affecting over 20 million people globally. As part of the agreement, Biogen will make Pfizer an…

Hopes for Alzheimer’s therapy focus on Biogen (aducanumab)

Academia and investors were dejected as Pfizer last week announced it would end research for Alzheimer’s treatments. The few multinationals still working on Alzheimer’s – Eli Lilly, Biogen and Novartis – have recently said they are determined to keep funding…

Pfizer signs $160m cooperation agreement with Sangamo Therapeutics

Pfizer and Sangamo Therapeutics have announced a cooperation aimed at using the “zinc finger therapy” for the treatment of ALS linked to mutations of the C9ORF72 gene. Thanks to the agreement, Sangamo will receive $12m from Pfizer, plus a potential…

Teva launches Viagra generic in US

Viagra was approved by FDA in 1998 and has fetched Pfizer billions of dollars worldwide since then. Considering the 2003-2014 period, Viagra’s total revenue is $21.975bn, that is $1.83bn per year on average. Viagra is sold at $65 in the…

Pfizer expands to Asia license agreement with Basilea for Cresemba

Switzerland-based pharmaceutical group Basilea has expanded the production and commercialization license granted to Pfizer for antibiotic Cresemba (isavuconazol) to China and 16 other Asian countries. The license has been limited to Europe, Russia, Turkey and Israel so far. The Switzerland-based…

M&A drive in pharma fading

Deals in pharma M&A in the first 9 months of the year totaled $66.4bn, equaling a 36% drop as compared to 2016. The decrease is even more significant when compared to 2015, when sales volume over the first three quarters…